Hand Grenade Guitars

@Spectre_Trader @Rrockypolos

@Spectre_Trader @Rrockypolos Oh, I know @Spectre_Trader there's still a long way to go.

@Rrockypolos @HandGrenad89912 #SVNS The current share price is still roughly 20% below the 0.33p placing price.

And so goes Q1 and missed deadlines. What also happened to the 'in discussions with 3 pharmas' at the end of Q4 2025? #svns Ant Tennyson can only string this along a little while longer before investors start to question his position. Today's news good but still too much promised

@that_stocks_guy @that_stocks_guy I started reading and I was wondering where the story about Mushu was going... Very well done.

#GRX #AET #XTR #SWT #ZEN #AJAX #AFC #ALRT #SVNS #IMM #UOG #STUD #HEX #JLP #AFP #ARS #UFO #BRES #BZT #POW #GMET #RMR #ARCM #SVML #AMRQ #GWMO #UPL #CMRS #ARK #ATN #FMET #DGQ #RiftHelium #ServalResources Your monthly review. Some volatility, but we're in it to win it. open.substack.com/pub/thatstocks…

@Rrockypolos @Spectre_Trader It is today. However, like the football team I support, it's better for everyone if I don't watch!

@HandGrenad89912 @Spectre_Trader Looking lively today. So all good it seems

@Rrockypolos @Spectre_Trader Supposedly, AT is due to have a chat on the Sunday Roast very soon.

@Spectre_Trader @HandGrenad89912 That's one thing that has got me waiting - funding. Pharma time lines are always way way out but why the silence on 'in discussions with 3 pharmas' at the end of last year? Is there no update on this? Still watching and hovering over the buy button #svns

@Spectre_Trader @Solvonis Three sizable buys popped up today. Fingers crossed it's people in the know and news is imminent.

#SVNS We are now in the final week of this quarter. @Solvonis has gone stale. Unless the SVN-002 PK bridge data provides a significant surprise. With WuXi Apptech also guided for this quarter. The stock will likely remain range-bound.

@Spectre_Trader @Rrockypolos solvonis.com/news/svn-114-s…

@HandGrenad89912 @Rrockypolos This interview from one year ago is crucial. In it, Tennyson meticulously explains the rationale for integrating the Awakn assets into the Solvonis structure and underscores the immediate value this created for the new shareholders. youtu.be/1LtBlvfnJmc?si…

#SVNS The market seems to lack confidence in Tennyson's ability to close deals. Is this a biotech or lifestyle company? Only time will tell.

@Spectre_Trader @Rrockypolos Very strange.

@Rrockypolos @HandGrenad89912 Anthony Tennyson is back on X. His short hiatus didn't last long.

@Rrockypolos @Spectre_Trader Aye, who knows, mate. Let's see what next week brings.

@Spectre_Trader @D4V3Y @Solvonis Absolutely, there's still lots more to come.

@D4V3Y @HandGrenad89912 @Solvonis #SVNS I'm here for the Q1 milestones, the in-vivo work and lead candidate selection is necessary data to support licensing discussions. The next few weeks will determine the direction of travel.

@Spectre_Trader @Solvonis I'm hoping not, many at Solvonis have reputations to uphold and whilst we've been waiting, other developments have happened.

@HandGrenad89912 It's hard to say whether @Solvonis Management is simply resting on their laurels or if they are genuinely working hard.

@Spectre_Trader @investwisely321 @Solvonis @RoastPR He and the rest of the board are very articulate and transparent (as much as they can be). Like you, I'm waiting on the critical pieces of the puzzle to fall into place.

@HandGrenad89912 @investwisely321 @Solvonis @RoastPR #SVNS Great to see Anthony Tennyson articulating the Solvonis vision so clearly on recent podcasts. The valuation gap, thesis is now well-established. Eager to see less media and more lead-candidate selection data for SVN-SDN-14 soon.

#SVNS Anthony Tennyson’s operational delivery hasn't ignited interest, leading to a breakdown in conviction and forced selling. However, unless @Solvonis signals otherwise, the Q1 roadmap (PTSD lead selection & NIDA data) remains the binary trigger.

@Spectre_Trader @investwisely321 @Solvonis @RoastPR To be brutally honest I've found the style and quality of questions on the roast to be poor, especially when compared to Water Tower Research interview that Anthony Tennyson did a spell back.

@investwisely321 @Solvonis #SVNS Anthony Tennyson is probably preparing for the @RoastPR podcast again? I hope he’s bringing the Q1 lead-candidate selection as a side dish. Focus on the tangible milestones.

@Spectre_Trader It is indeed frustrating, @Spectre_Trader We need a NASDAQ listing and hopefully then we'll see a valuation that reflects what #SVNS has to offer.

#SVNS Another solid RNS from Solvonis Therapeutics expanding SVN-015 into depression, yet the share price remains pinned. Frustrating to see the clinical progress ignored by the market. Waiting for the selling pressure to finally exhaust so the valuation can reflect the pipeline.

@Spectre_Trader @Spectre_Trader CEO has said that they are funded through 2027.

@Spectre_Trader I am, yes. There's a couple hundred of us on there now and it keeps growing. Migrated over from the LSE board.

@HandGrenad89912 I'm not in the Telegram group.

#SVNS Needs a hard clinical data readout or a major commercial partnership.